吲唑-5-甲酸甲酯 | 473416-12-5

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 吲唑-5-甲酸甲酯
• 中文别名: 甲基吲唑-5-羧酸酯；1H-吲唑-5-羧酸甲酯；1H-吲唑-5-甲酸甲酯；吲唑-5-羧酸甲酯
• 英文名称: methyl 1H-indazole-5-carboxylate
• 英文别名: 1H-indazole-5-carboxylic acid methyl ester；methyl indazole-5-carboxylate
• CAS: 473416-12-5
• 化学式: C₉H₈N₂O₂
• 分子量: 176.175
• InChiKey: LPLOEZPPYOSNEW-UHFFFAOYSA-N

物化性质

• 沸点：
  345.2±15.0 °C(Predicted)
• 密度：
  1.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl indazole-5-carboxylate
Synonyms: Methyl 1H-indazole-5-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl indazole-5-carboxylate
CAS number: 473416-12-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8N2O2
Molecular weight: 176.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

吲唑-5-甲酸甲酯是一种广泛应用于有机合成和医药领域的中间体，主要在实验室研发及化工生产过程中发挥重要作用。

反应信息

• 作为反应物：
  描述：

  吲唑-5-甲酸甲酯 在 N-溴代丁二酰亚胺(NBS) 、 palladium 10% on activated carbon 、 氢气 、 sodium hydride 、 caesium carbonate 、 sodium hydroxide 、 lithium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 、 mineral oil 为溶剂， 反应 18.83h， 生成 3-甲基-1H-吲唑-5-羧酸
  参考文献：
  名称：

  [EN] N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG
  [FR] MODULATEURS N-ARYLYLMÉTHYLINDAZOLES DE PPARG

  摘要：

  该发明提供了与PPARG（PPARγ）高亲和力结合的分子实体，能够抑制cdJk5介导的PPARG磷酸化，但不对PPARG产生激动作用。该发明的化合物可用于治疗PPARG在糖尿病或肥胖等病患中发挥作用的情况。该发明还提供了制备这些化合物的方法、用于评估该发明的非激动性PPARG结合化合物的生物测定方法，以及制药组合物。

  公开号：

  WO2013078237A1
• 作为产物：
  描述：

  吲唑-5-甲酸盐酸盐 在 草酰氯 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 吲唑-5-甲酸甲酯
  参考文献：
  名称：

  [EN] N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG
  [FR] MODULATEURS N-ARYLYLMÉTHYLINDAZOLES DE PPARG

  摘要：

  该发明提供了与PPARG（PPARγ）高亲和力结合的分子实体，能够抑制cdJk5介导的PPARG磷酸化，但不对PPARG产生激动作用。该发明的化合物可用于治疗PPARG在糖尿病或肥胖等病患中发挥作用的情况。该发明还提供了制备这些化合物的方法、用于评估该发明的非激动性PPARG结合化合物的生物测定方法，以及制药组合物。

  公开号：

  WO2013078237A1
• 作为试剂：
  描述：

  吲唑-5-甲酸盐酸盐 、 水 、 甲醇 在 乙酸乙酯 、 碳酸氢钠 、 Brine 、 magnesium sulfate 、 吲唑-5-甲酸甲酯 作用下， 以 硫酸 为溶剂， 反应 0.08h， 生成 吲唑-5-甲酸甲酯
  参考文献：
  名称：

  COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE

  摘要：

  本发明提供了一种化合物，即1-（{卤代2-[(2-烃基或取代烃基)氧基]苯基}甲基）-（融合的双环氮杂芳基）羧酸或其酯或磺酰胺。该化合物可由下式表示： 其中R1，R2，R3，R4A，X，W，Z和Y如说明书中所定义。这些化合物可用于治疗DP，FP，EP1，TP和/或EP4受体介导的疾病或病状。

  公开号：

  US20130184463A1

文献信息

• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20120277224A1

  公开（公告）日：2012-11-01

  Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了新的杂环化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制PAS激酶（PASK）在人类或动物主体中活性的方法，用于治疗疾病，如糖尿病。
• Indazole-derivatives as factor Xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1479675A1

  公开（公告）日：2004-11-24

  The present invention relates to compounds of the formulae I and Ib wherein R0 ; R1 ; R2 ;Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and Ib, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I和Ib的化合物 其中R0; R1; R2; Q; V，G和M具有索赔中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血液凝块酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于因子Xa和/或因子VIIa的不良活性存在或因子Xa和/或因子VIIa的抑制而打算治愈或预防的情况。此外，本发明还涉及制备式I和Ib的化合物的方法，它们的用途，特别是作为药物中的活性成分，并包括它们的制药制剂。
• [EN] PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PYRAZOLOSPIROCÉTONE ACÉTL-COA CARBOXYLASE
  申请人：PFIZER

  公开号：WO2009144554A1

  公开（公告）日：2009-12-03

  The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供了式(1)的化合物或所述化合物的药用可接受盐，其中R1、R2和R3如本文所述；其药物组合物；以及用于治疗通过抑制动物中的乙酰辅酶A羧化酶酶活性来调节的疾病、病症或障碍的使用方法。
• [EN] SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME<br/>[FR] AMIDES TRICYCLIQUES SUBSTITUÉS, ANALOGUES DE CEUX-CI ET PROCÉDÉS LES METTANT EN OEUVRE
  申请人：ARBUTUS BIOPHARMA CORP

  公开号：WO2021229302A1

  公开（公告）日：2021-11-18

  The present disclosure includes substituted tricyclic amides, or analogues thereof of formula (I) (I), wherein X, Y, ring A, R1, R5, R6 and R7 are as defined herein, and compositions comprising compounds of formula (I) that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

  本公开涵盖了替代三环酰胺，或其类似物的化合物，其化学式为(I)，其中X、Y、环A、R1、R5、R6和R7如本文所定义，并包括化合物(I)的组合物，可用于治疗或预防患者体内的乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HDV）感染。
• One-Pot Synthesis of Novel 3,5-Disubstituted-1,2,4-oxadiazoles from Indazole Carboxylic Acid Esters and Amidoximes
  作者：Udutha Kumara Swamy、H. Rama Mohan、U. Viplava Prasad、T. Suresh、T. Laxmi Kumar

  DOI：10.14233/ajchem.2014.15564

  日期：——

  An efficient and high-yielding one-pot synthesis of 3,5-disubstituted-1,2,4-oxadiazoles from indazole carboxylic acid methyl esters and amidoximes is described. In this study a series of novel 3,5-disubstituted-1,2,4-oxadiazoles (3a-d), (4a-d), (5a-d), (6a-d), (7a-d) were synthesized using amidoximes 2a-d and indazole carboxylic acid esters (3-6).

  本文描述了一种高效且高产率的一锅法合成3,5-二取代-1,2,4-噁二唑的方法，该方法从吲唑羧酸甲酯和酰肟出发。在本研究中，利用酰肟2a-d和吲唑羧酸酯（3-6）合成了一系列新型3,5-二取代-1,2,4-噁二唑（3a-d）、（4a-d）、（5a-d）、（6a-d）、（7a-d）。